Status | Study |
Completed |
Study Name: A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE) Condition: Gaucher Disease Date: 2010-02-23 Interventions: Drug: Eliglustat tartrate Oral Capsule in 50 mg or 100 mg dosages |
Approved for marketing |
Study Name: Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease Condition: Gaucher Disease, Type 1 Date: 2009-08-05 Interventions: Drug: velaglucerase alfa up to 60 U/kg, every other week via intravenous infusion |
Completed |
Study Name: A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) Condition: Gaucher Disease, Type 1 Date: 2009-07-20 Interventions: Drug: Eliglustat tartrate |
Completed |
Study Name: A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE) Condition: Gaucher Disease, Type 1 Date: 2009-04-30 Interventions: Drug: Eliglustat tartrate PAP: |
Terminated |
Study Name: A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101 Condition: Type 1 Gaucher Disease Date: 2009-04-02 Interventions: Drug: AT2101 225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days |
Completed |
Study Name: A Long-Term Extension Study of AT2101 in Type 1 Gaucher Patients Condition: Gaucher Disease Type 1 Gaucher Disease Date: 2008-12-22 Interventions: Drug: AT2101 AT2101 oral capsules Other Name: AT2101 |
Completed |
Study Name: An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease Condition: Gaucher Disease, Type 1 Date: 2008-03-06 Interventions: Biological: VPRIV® Intravenous infusion, every other week (EOW) |
Completed |
Study Name: Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase Condition: Gaucher Disease, Type 1 Date: 2007-05-23 Interventions: Biological: GA-GCB (velaglucerase alfa) 15-60 U/kg, every other week via intravenous infusion |
Completed |
Study Name: Safety Study of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy Condition: Gaucher Disease, Type 1 Date: 2007-02-07 Interventions: Drug: AT2101 AT2101 25 mg orally once a day (25 mg capsule), AT2101 150mg (six 25 mg capsules)once a day |
Completed |
Study Name: Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT) Condition: Gaucher Disease Date: 2006-10-20 Interventions: Drug: GA-GCB 15-60 U/kg every other week via intravenous infusion |